Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients

Oliver Cooper, Arnar Astradsson, Penny Hallett, Harold Robertson, Ivar Mendez, Ole Isacson, Oliver Cooper, Arnar Astradsson, Penny Hallett, Harold Robertson, Ivar Mendez, Ole Isacson

Abstract

Postmortem analyses from clinical neural transplantation trials of several subjects with Parkinson's disease revealed surviving grafted dopaminergic neurons after more than a decade. A subset of these subjects displayed isolated dopaminergic neurons within the grafts that contained Lewy body-like structures. In this review, we discuss why this isolated cell damage is unlikely to affect the overall graft function and how we can use these observations to help us to understand age-related neurodegeneration and refine our future cell replacement therapies.

References

    1. J Clin Invest. 2009 Jan;119(1):13-5
    1. N Engl J Med. 1995 Apr 27;332(17):1118-24
    1. Brain. 2005 Jul;128(Pt 7):1498-510
    1. Parkinsonism Relat Disord. 2008;14 Suppl 2:S112-5
    1. Ann Neurol. 2003;53 Suppl 3:S135-46; discussion S146-8
    1. Mov Disord. 2006 May;21(5):624-31
    1. Lancet Neurol. 2003 Jul;2(7):417-24
    1. N Engl J Med. 2001 Mar 8;344(10):710-9
    1. Nat Med. 2008 May;14(5):501-3
    1. Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5856-61
    1. J Neurosci. 1994 Dec;14(12):7553-62
    1. Ann N Y Acad Sci. 2003 Jun;991:1-14
    1. J Neurosurg. 1994 Aug;81(2):272-83
    1. Brain. 2007 Jul;130(Pt 7):1819-33
    1. Mov Disord. 2008 Dec 15;23(16):2303-6
    1. J Neurosci. 2007 Jul 25;27(30):8011-22
    1. Nat Neurosci. 1999 Dec;2(12):1137-40
    1. Neurobiol Dis. 2008 Jan;29(1):103-16
    1. J Neuroinflammation. 2008 Feb 27;5:8
    1. Ann Neurol. 1994 Feb;35(2):172-80
    1. Hum Mol Genet. 2005 Jul 1;14(13):1709-25
    1. Neurobiol Dis. 2009 Sep;35(3):348-51
    1. Nat Rev Neurosci. 2008 Oct;9(10):741-5
    1. Neurosurg Focus. 2008;24(3-4):E6
    1. Brain. 2005 Oct;128(Pt 10):2240-9
    1. N Engl J Med. 1998 Oct 15;339(16):1105-11
    1. Eur J Neurosci. 2008 Jun;27(12):3205-15
    1. Brain. 2008 Oct;131(Pt 10):2720-8
    1. J Comp Neurol. 2007 Jun 10;502(5):683-700
    1. J Neurosurg. 2002 Mar;96(3):589-96
    1. N Engl J Med. 1992 Nov 26;327(22):1541-8
    1. Stem Cells. 2008 Jun;26(6):1526-36
    1. Ann Neurol. 2008 Dec;64 Suppl 2:S122-38
    1. Nat Med. 2008 May;14(5):504-6
    1. Neurosurgery. 1994 Dec;35(6):1126-9; discussion 1129-30
    1. Ann Neurol. 2003 Sep;54(3):403-14
    1. J Neurosci. 2008 Jul 23;28(30):7687-98
    1. Mov Disord. 1998 May;13(3):383-93
    1. Arch Neurol. 1999 Feb;56(2):179-87
    1. N Engl J Med. 2003 Nov 13;349(20):1925-34
    1. Lancet. 1995 Jan 14;345(8942):91-5
    1. N Engl J Med. 1992 Nov 26;327(22):1556-63
    1. Clin Immunol. 2008 Sep;128(3):294-305
    1. Science. 1990 Feb 2;247(4942):574-7
    1. Nat Med. 2008 May;14(5):507-9
    1. Ann Neurol. 2000 Nov;48(5):689-95

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi